Sunesis Pharmaceuticals Inc. (formerly known as Mosaic Pharmaceuticals)

Brief Description

Sunesis is a biopharmaceutical company focused on the development and future commercialization of new oncology therapeutics for the treatment of hematologic and solid tumor cancers. Sunesis has built an experienced cancer drug development organization committed to improving the lives of people with cancer. The company is focused on advancing its novel kinase-inhibitor pipeline, with an emphasis on establishing proof of concept that it's oral non-covalent BTK inhibitor, vecabrutinib (SNS-062), is effective in the treatment of ibrutinib-resistant chronic lymphocytic leukemia.


Jonathan Ellman

Tech Category

  • Medical Therapeutics

Join the IPIRA Mailing List




Accessibility | Nondiscrimination | Privacy